An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.

Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by the loss of function of the maternally inherited ...

US pharma major Bristol Myers Squibb has announced that the Phase III EXCALIBER-RRMM study evaluating iberdomide, an ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD™), combined with standard ...

Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein ...

Monte Rosa Therapeutics stock surged after expanding its Novartis partnership. Click here to learn about their innovative ...

The EXCALIBER-RRMM study evaluated the efficacy and safety of iberdomide, an investigational cereblon E3 ligase modulator, in combination with dexamethasone and daratumumab in adults with RRMM.

Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for ...